OAB and Incontinence

Jeffrey P. Weiss, MD, PhD, discusses how he defines nocturia, how to separate the symptom from overactive bladder, and how he conducts patient work-ups for nocturia

Data from a pivotal trial showed the eCoin Peripheral Neurostimulator led to a clinically significant improvement in urgency urinary incontinence.

Beta 3-adrenergic receptor agonist’s benefits observed at 52 weeks, investigators report.

The OASIS study is examining the RENOVA iStim implantable tibial neuromodulation system for the treatment of women with overactive bladder.

InterStim Micro treats patients with overactive bladder, fecal incontinence, and non-obstructive urinary retention by delivering sacral neuromodulation therapy.

Feasibility study results indicate the nonimplanted, intravaginal device is safe and comfortable.

Treatment with litoxetine, an investigational oral selective serotonin reuptake inhibitor, led to nearly 22% of patients becoming continent.

The reduction in urinary urgency incontinence episodes observed was “quite significant,” an investigator said.

Urologists must differentiate between bladder outlet obstruction and pure OAB in male patients, according to Osvaldo F. Padron, MD.

An investigational wireless, implantable tibial nerve stimulator is safe and provided improvement in overactive bladder symptoms over 3 years of follow-up.

Mirabegron (Myrbetriq) is effective and well tolerated in patients age 65 or older with overactive bladder, results of a randomized, placebo-controlled study show.

A recent study found that sacral neuromodulation monotherapy was efficacious as a third-line treatment.

Nocturia appears to be highly prevalent in the United States, with almost 30% of all women reporting significant nocturia, according to new data reported at the AUA annual meeting in San Francisco.

 Waking up at night to urinate is by far the most bothersome lower urinary tract symptom. 

The therapeutic efficacy of sacral neuromodulation was not affected by non-head magnetic resonance imaging scans in a recent study.

Over half of patients stop intradetrusor botulinum toxin injections within 10 years, mostly due to lack of clinical efficacy, researchers say.

In this interview, J. Quentin Clemens, MD, discusses the work being done by the MAPP (Multidisciplinary Approach to Chronic Pelvic Pain) Research Network and LURN (Symptoms of Lower Urinary Tract Dysfunction Research Network) research initiatives.

“The results suggest that this compound has rapid efficacy and a favorable safety profile in patients with nocturia due to nocturnal polyuria,” says researcher Diane Newman, DNP.

Cost-effectiveness results favored botulinum toxin at 2 years as well as in an analysis at 5 years accounting for increased cost of the botulinum approach due to repeat injections, according to investigator Heidi S. Harvie, MD, MSCE.

In women with mixed urinary incontinence, a combined conservative and surgical treatment approach provided significant improvements versus surgical treatment alone.

Among patients with a clinical response 1 month after implantation, most went on to have clinically and statistically significant reductions in overactive bladder symptoms at 1 year.

Researchers retrospectively reviewed the records of a series of patients who underwent onabotulinumtoxinA (Botox) injections for overactive bladder from 2007 to 2017.

Nocturnal polyuria can't be diagnosed using a standard history alone, researchers say.